Controversies of androgen ablation therapy for metastatic prostate cancer

Current Pharmaceutical Design

Volumn 12, Issue 7, 2006, Pages 799-805

  Wilson, Shandra S ^a,b   Crawford, E David ^a  

^a Anschutz Cancer Center   (United States)

^b Department of Urologic Oncology ^*  (United States)

Author keywords

Androgen deprivation; Anti androgen monotherapy; Chemotherapy; Combined androgen blockade; Early hormonal treatment; Intravenous bisphosphonates; Neoadjuvant therapy; Prostatic neoplasm

Indexed keywords

ABARELIX; ANASTROZOLE; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CYPROTERONE ACETATE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; ETOPOSIDE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PLACEBO; PREDNISONE; RHENIUM 188; STEROID 5ALPHA REDUCTASE INHIBITOR; STRONTIUM 89; SURAMIN; TAMOXIFEN; UNINDEXED DRUG; VINBLASTINE; ZOLEDRONIC ACID;

BONE METASTASIS; BONE PAIN; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CRYOTHERAPY; DISEASE FREE SURVIVAL; DRUG INTERMITTENT THERAPY; ERECTILE DYSFUNCTION; GYNECOMASTIA; HORMONE INHIBITION; HUMAN; MALE; MASTALGIA; META ANALYSIS; METASTASIS; MONOTHERAPY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; METHODOLOGY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 33645288025     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776056056     Document Type: Review

References (69)

1. Huggins C, Hodges CV. Studies on prostatic cancer: effect of castration, of estrogen and androgen injection on serum phophatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
2. Zelefsky MJ, Leibel SA, Kutcher GJ, Fuks Z. Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 1998; 8: 107-14.
3. Potters L, Torre T, Ashley R, Leibel S. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000; 18: 1187-92.
4. Kucway R, Vicini F, Huang R, Stromberg J, Gonzalez J, Martinez A. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002; 167: 2443-7.
5. Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA. Higher than standard radiation doses (>72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 46: 567-74.
6. D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000; 284: 1280-3.
7. Pilepich MY, Caplan RW, Byhardt RW, Lawton CA, Gallagher MD, Mesic JB, et al. Phase III trail of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of the Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15(3): 1013-21.
8. Pilepich MV, Winter K, Roach M. Phase III Radiation Therapy Oncology (RTOG) Trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. American Society of Clinical Oncology, Los Angeles 1998; 308a.
9. Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Doggett RL, Sause WT, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45(4): 616-23.
10. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
11. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, et al. Predicting long-term survival and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Rad Oncol Biol Phys 2000; 47(3): 617-27.
12. de la Taille A, Hayek O, Benson MC, Bagiella E, Olsson CA, Fatal M, et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology 2000; 55: 79-84.
13. Klotz LH, Glodenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, et al. Long-term follow-up of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170: 791-4.
14. Soloway MS, Pareek K, Sharifi R, Wassman Z, McLeod D, Wood DP, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J Urol 2002; 167: 112-6.
15. Aus G, Abrahammsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M. Hormonal treatment before radical prostatectomy: a 3-year follow-up. J Urol 1998; 159: 2013-6.
16. Wildschutz T, Louis L, Hourriez L. Neoadjuvant hormonal treatment prior to radical prostatectomy: follow-up of a prospective randomized study. Eur Urol 1996; 30: 210, abstract 774.
17. Meyer F, Bairati I, Bedard C, Lacombe L, Tetu B, Fradet Y, et al. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer. Urology 2001; 58: 71-7.
18. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166: 500-5.
19. Schulman CC, Debruyne FM, Forster G, Selvaggi F, Zlott AR, Witses WP, et al. 4-year follow-up results of a European Prospective Randomized Study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000; 38(6): 706-13.
20. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 2000; 355: 1491-8.
21. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD, et al. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trial and 4128 patients using flutamide. Prostate Cancer Prostate Dis 1999; 2: 4-8.
22. Akaza H, Homma Y, Okada K, Yokoyama M, Usami M, Hirao Y. A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up. BJU Int 2003; 9(1): 33-6.
23. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15):1036-42.
24. Pound CR, Partin AW, Eisenberger MA, Chad DW, Pearson JD, Walsh PC, et al. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999; 281(17): 1591-7.
25. Medical Research Council. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial. B J Urol 1997; 79: 235-46.
26. Messing E, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Eng J Med 1999; 341(24):1781-88.
27. Van den Ouden, Tribukait B, Blom JH, Foss SD, Kurth KH, Tenkate FJ, et al. Deoxyribonuclic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. European Organization for Research and Treatment of Cancer Genituourinary Group. J Urol 1993; 150: 400-6.
28. Zincke H, Lau W, Bergstralh E, Blute ML. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001; 166(6): 2208-15.
29. Studer UE, Hauri D, Dietrich D. Immediate vs. deferred hormonal therapy for prostate cancer patients not suitable for curative local treatment (abstract). J Urol 2002; 167: 303.
30. Kramolowsky EV. The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 1988; 139: 1242.
31. Zagars GK, Pollack A, von Eschenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 2001; 58(2): 233-9.
32. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma; early versus late endocrine therapy. Urol Clin Nor Am 1991; 18(1): 15-24.
33. Kurek R, Renneberg H, Lubben G, Kienle E, Tunn VW. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999; 35(suppl 1): 27-31.
34. Olsson CA, Dennis JJ, Miller GL. 2003 Annual Meeting Convention Highlights. Med Assoc Commun 2003; pp. 15.
35. Bruchovsky N, Klotz LH, Sadar M, Crook JM, Hoffart D, Godwin L. Intermittent androgen suppression for prostate cancer: Canadian prospective trial and related observations. Mol Urol 2000; 4: 191-9.
36. Tarle M, Ahel MZ, Kovicic K. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Anticancer Res 2002; 22(4): 2525-9.
37. Sciarra A, Monti S, Genitle V, Mariotti G, Cardi A, Voria G. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003; 55(3): 168-79.
38. Wirth M, See W, McLeod D. Bicalutamide ('Cassodex') 150mg as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer. Proc Am Soc Clin Oncol 2001; 20: 177a (abstract).
39. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999; 17(7): 2027-38.
40. Boccardo F, Barichello M, Battaglia M, Carmignani G, Comeri G, Ferrais V, et al. Bicalutamide monotherapy versus flutamide plus goserlin in prostate cancer: Updated results of a multicentric trial. Eur Urol 2002; 42(5): 481-90.
41. Iversen P, Tyrrell CJ, Kaisary AV Anderson JB, Van Poppel H, Tammela TL, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000; 164: 1579-82.
42. Olsson CA, Dennis JJ, Miller GL. 2003 Annual Meeting Convention Highlights. Med Assoc Commun 2003; pp. 4.
43. Widmark A, Fossa SD, Lundmo P, Damber JE, Vaage S, Damber L, et al. Does prophylactic breast irradiation prevent anti-androgeninduced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003; 61(1): 145-51.
44. Orenstein DK, Rao GS, Johnson B, Charlton ET, Andriole GL, et al. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996; 48(6): 901-5.
45. Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001; 165: 1585-9.
46. Beer TM, Garzotto M, Eilers KM, Lemmon D. Phase II study of abarelix depot for androgen independent prostate cancer progressions during gonadotropin-releasing hormone agonist therapy. J Urol 2003; 169(5): 1738-41.
47. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003; 21(15): 2869-75.
48. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001; 357(9253): 336-41.
49. Olsson CA, Dennis JJ, Miller GL. 2003 Annual Meeting Convention Highlights. Medical Association Communications 2003; pp. 16.
50. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6: 2175-82.
51. Small EJ, Fratesi P, Resse DM, Strang G, Laus R, Peshua MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894-903.
52. Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM, et al. Phase II trial of Suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997; 15: 1470-7.
53. Koutsilieris M, Mitsiades C, Dimopoulos T. Combination of dexamethasone and somatostatin analogue in the treatment of advanced prostate cancer. Exp Opin Invest Drugs 2002; 11(2): 283-93.
54. Straub B, Muller M, Krause H. Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer. Urology 2003; 62(1): 172-6.
55. Montgomery JS, Price DK, Figg WD. The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol 2001; 195(2): 138-46.
56. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20(13): 3001-15.
57. Mu X, Chang C. TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3. Prostate 2003; 57(2): 129-33.
58. Smith MR, Estham J, Gleason DM. Randomized controlled trial of zolendronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. J Urol 2003; 169(6): 2008-12.
59. Saad F, Gleason DM, Murray R. A randomized, placebo-controlled trial of zolendronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94(19): 1458-68.
60. Novick A. Effect of fracture on survival in men treated with androgen deprivation for prostate cancer. J Urol 2002; 168: 1005-7.
61. Schmidt J, Gibbons R, Murphy G. Adjuvant estramustine phosphate treatment for localized prostate cancer. PPO Updates 1997; 11:1.
62. Wang J. Halford S. Rigg A, Roylance R, Lynch M, Waxman J, et al. Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. BJU Int 2000; 86(6): 675-80.
63. Pummer K, Lehnert M, Stettner H, Hubmer G. Randomized comparison of total androgen blockade along verses combined with weekly epirubicin in advanced prostate cancer. Eur Urol Suppl 1997;32:81.
64. Fossa SD, Curran D, Aaronson NK. Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893. Eur Urol 2000; 37(5): 541-51.
65. Pettaway C, Pisters L, Troncoso P. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000; 15(5): 1050-7.
66. Bagley CM, Lane RF, Blasko JC. Adjuvant chemohormonal therapy of high-risk prostate carcinoma; ten year results. Cancer 2002; 94: 2728-32.
67. Closset J, Ammar H, Nguyen VH, Cornet A, Reiter E. New features in the treatment of androgen-independent prostate cancer. Curr Pharm Des 2004; 10(5): 513-22.
68. Leuschner C, Hansel W. Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des 2004; 10(19):2299-310.
69. Maitland NJ, Stanbridge LJ, Dussupt V. Targeting gene therapy for prostate cancer. Curr Pharm Des 2004; 10(5): 531-55.